Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding
Published inThrombosis and haemostasis, vol. 117, no. 1, p. 196-197
Publication date2017-01-05
First online date2016-10-13
Keywords
- Acute Kidney Injury / diagnosis
- Acute Kidney Injury / etiology
- Acute Kidney Injury / physiopathology
- Acute Kidney Injury / therapy
- Aged
- Antibodies, Monoclonal, Humanized / administration & dosage
- Antibodies, Monoclonal, Humanized / pharmacokinetics
- Antidotes / administration & dosage
- Antidotes / pharmacokinetics
- Antithrombins / adverse effects
- Atrial Fibrillation / blood
- Atrial Fibrillation / diagnosis
- Atrial Fibrillation / drug therapy
- Dabigatran / adverse effects
- Dabigatran / antagonists & inhibitors
- Hemorrhage / blood
- Hemorrhage / chemically induced
- Hemorrhage / diagnosis
- Hemorrhage / drug therapy
- Hemostasis / drug effects
- Humans
- Male
- Severity of Illness Index
- Treatment Outcome
Affiliation entities Not a UNIGE publication
Citation (ISO format)
QUINTARD, Hervé et al. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding. In: Thrombosis and haemostasis, 2017, vol. 117, n° 1, p. 196–197. doi: 10.1160/TH16-06-0445
Main files (1)
Article (Published version)
Identifiers
- PID : unige:190270
- DOI : 10.1160/TH16-06-0445
- PMID : 27734073
Additional URL for this publicationhttps://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH16-06-0445
Journal ISSN0340-6245
